Effect of metallothionein 2A gene polymorphism on allele-specific gene expression and metal content in prostate cancer

Toxicology and Applied Pharmacology

Volumn 268, Issue 3, 2013, Pages 278-285

  Krześlak, Anna ^a   Forma, Ewa ^a   Chwatko, Grazyna ^a   Jóźwiak, Paweł ^a   Szymczyk, Agnieszka ^a   Wilkosz, Jacek ^b   Rózański, Waldemar ^b   Bryś, Magdalena ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Gene expression; Metallothionein 2A; Metals; Polymorphism; Prostate cancer

Indexed keywords

CADMIUM; LEAD; METALLOTHIONEIN II; ZINC;

ALLELE; ARTICLE; CANCER TISSUE; CORRELATION COEFFICIENT; GENE EXPRESSION; GENETIC ANALYSIS; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SPECTROMETER;

AGED; ALLELES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; METALLOTHIONEIN; METALS, HEAVY; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; ZINC;

EID: 84875328233     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.02.013     Document Type: Article

References (48)

1. Achanzar W.E., Diwan B.A., Liu J., Quader S.T., Webber M.M., Waalkes M.P. Cadmium-induced malignant transformation of human prostate epithelial cells. Cancer Res. 2001, 61:455-458.
2. Alvarez S.M., Gomez N.N., Scardapane L., Zirulnik F., Martinez D., Gimenez M.S. Morphological changes and oxidative stress in rat prostate exposed to a non-carcinogenic dose of cadmium. Toxicol. Lett. 2004, 153:365-376.
3. Benbrahim-Tallaa L., Waterland R.A., Dill A.L., Webber M.M., Waalkes M.P. Tumor suppressor gene inactivation during cadmium-induced malignant transformation of human prostate cells correlates with overexpression of de novo DNA methyltransferase. Environ. Health Perspect. 2007, 115:1454-1459.
4. Beyersmann D., Hartwig A. Carcinogenic metal compounds: recent insight into molecular and cellular mechanisms. Arch. Toxicol. 2008, 82:493-512.
5. Bittel D., Dalton T., Samson S.L., Gedamu L., Andrews G.K. The DNA binding activity of metal response element-binding transcription factor-1 is activated in vivo and in vitro by zinc, but not by other transition metals. J. Biol. Chem. 1998, 273:7127-7133.
6. Bryś M., Nawrocka A.D., Mieogonekkoś E., Zydek C., Foksiński M., Barecki A., Krajewska W.M. Zinc and cadmium analysis in human prostate neoplasms. Biol. Trace Elem. Res. 1997, 57:145-152.
7. Cherian M.G., Jayasurya A., Bay B.H. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat. Res. 2003, 533:201-209.
8. Costello L.C., Franklin R.B., Feng P. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion 2005, 5:143-153.
9. Coyle P., Philcox J.C., Carey L.C., Rofe A.M. Metallothionein: the multipurpose protein. Cell Mol. Life Sci. 2001, 59:627-647.
10. Das K., Nag C., Ghosh M. Familial environmental and occupational risk factors in development of amyotrophic lateral sclerosis. North Am. J. Med. Sci. 2012, 4:350-355.
11. Dziegiel P. Expression of metallothioneins in tumor cells. Pol. J. Pathol. 2004, 55:3-12.
12. Forma E., Krzeslak A., Wilkosz J., Szymczyk A., Rozanski W., Brys M. Metallothionein 2A genetic polymorphisms and risk of prostate cancer in Polish population. Cancer Genet. 2012, 205:432-435.
13. Franklin R.B., Costello L.C. Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch. Biochem. Biophys. 2007, 463:211-217.
14. Giacconi R., Cipriano C., Muti E., Costarelli L., Maurizio C., Saba V., Gasparini N., Malavolta M., Mocchegiani E. Novel -209A/G MT2A polymorphism in old patients with type 2 diabetes and atherosclerosis: relationship with inflammation (IL-6) and zinc. Biogerontology 2005, 6:407-413.
15. Giacconi R., Muti E., Malavolta M., Cipriano C., Costarelli L., Bernardini G., Gasparini N., Mariani E., Saba V., Boccoli G., Mocchegiani E. The +838 C/G MT2A polymorphism, metals, and the inflammatory/immune response in carotid artery stenosis in elderly people. Mol. Med. 2007, 13:388-395.
16. Giedroc D.P., Chen X., Apuy J.L. Metal response element (MRE)-binding transcription factor-1 (MTF-1): structure, function, and regulation. Antioxid. Redox Signal. 2001, 3:577-596.
17. Gillis B.S., Arbieva Z., Gavin I.M. Analysis of lead toxicity in human cells. BMC Genomics 2012, 13:344.
18. Gurer H., Ercal N. Can antioxidants be beneficial in the treatment of lead poisoning?. Free Radic. Biol. Med. 2000, 29:927-945.
19. Hamer D.H. Metallothionein. Annu. Rev. Biochem. 1986, 55:913-951.
20. Haq F., Mahoiney M., Kropatnicki J. Signaling events for metallothionein induction. Mutat. Res. 2003, 533:211-226.
21. Joseph P. Mechanisms of cadmium carcinogenesis. Toxicol. Appl. Pharmacol. 2009, 238:272-279.
22. Kägi J.H., Schäffer A. Biochemistry of metallothionein. Biochemistry 1988, 27:8509-8515.
23. Kayaalti Z., Mergen G., Söylemezoǧlu T. Effect of metallothionein core promoter region polymorphism on cadmium, zinc and copper levels in autopsy kidney tissues from a Turkish population. Toxicol. Appl. Pharmacol. 2010, 245:252-255.
24. Kayaalti Z., Aliyev V., Söylemezoǧlu T. The potential effect of metallothionein 2A -5A/G single nucleotide polymorphism on blood cadmium, lead, zinc and copper levels. Toxicol. Appl. Pharmacol. 2011, 256:1-7.
25. Kita K., Miura N., Yoshida M., Yamazaki K., Ohkubo T., Imai Y., Naganuma A. Potential effect on cellular response to cadmium of a single-nucleotide A → G polymorphism in the promoter of the human gene for metallothionein IIA. Hum. Genet. 2006, 120:553-560.
26. Navarro Silvera S.A., Rohan T.E. Trace elements and cancer risk: a review of the epidemiologic evidence. Cancer Causes Control 2007, 18:7-27.
27. Nemec A.A., Leikauf G.D., Pitt B.R., Wasserloos K.J., Barchowsky A. Nickel mobilizes intracellular zinc to induce metallothionein in human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 2009, 41:69-75.
28. Nielson K.B., Atkin C.L., Winge D.R. Distinct metal-binding configurations in metallothionein. J. Biol. Chem. 1985, 260:5342-5350.
29. Ozmen H., Erulas F.A., Karatas F., Cukurovali A., Yalcin O. Comparison of the concentration of trace metals (Ni, Zn, Co, Cu and Se), Fe, vitamins A, C and E, and lipid peroxidation in patients with prostate cancer. Clin. Chem. Lab. Med. 2006, 44:175-179.
30. Patrick L. Lead toxicity part II: the role of free radical damage and the use of antioxidants in the pathology and treatment of lead toxicity. Altern. Med. Rev. 2006, 11:114-127.
31. Pedersen M.Ø., Larsen A., Stoltenberg M., Penkowa M. The role of metallothionein in oncogenesis and cancer prognosis. Prog. Histochem. Cytochem. 2009, 44:29-64.
32. Ren Y., Zhou J.P., Zhang W.H., Feng W.H., Jiao B.H. Metallothionein gene expression under different time in testicular Sertoli and spermatogenic cells of rats treated with cadmium. Reprod. Toxicol. 2003, 17:219-227.
33. Sabolić I., Breljak D., Skarica M., Herak-Kramberger C.M. Role of metallothionein in cadmium traffic and toxicity in kidneys and other mammalian organs. Biometals 2010, 23:897-926.
34. Sapota A., Drago A., Taczalski J., Kilanowicz A. Disturbed homeostasis of zinc and other essential elements in the prostate gland dependent on the character of pathological lesions. Biometals 2009, 22:1041-1049.
35. Sarafanov A.G., Todorov T.I., Kajdacsy-Balla A., Gray M.A., Macias V., Centeno J.A. Analysis of iron, zinc, selenium and cadmium in paraffin-embedded prostate tissue specimens using inductively coupled plasma mass-spectrometry. J. Trace Elem. Med. Biol. 2008, 22:305-314.
36. Sato M., Kondoh M. Recent studies on metallothionein: protection against toxicity of heavy metals and oxygen free radicals. Tohoku J. Exp. Med. 2002, 196:9-22.
37. Tekin D., Kayaalti Z., Söylemezoǧlu T. The effects of metallothionein 2A polymorphism on lead metabolism: are pregnant women with a heterozygote genotype for metallothionein 2A polymorphism and their newborns at risk of having higher blood lead levels?. Int. Arch. Occup. Environ. Health 2012, 85:631-637.
38. Theocharis S., Karkantaris C., Philipides T., Agapitos E., Gika A., Margeli A., Kittas C., Koutselinis A. Expression of metallothionein in lung carcinoma: correlation with histological type and grade. Histopathology 2002, 40:143-151.
39. Theophanides T., Anastassopoulou J. Copper and carcinogenesis. Crit. Rev. Oncol. Hematol. 2002, 42:57-64.
40. Thirumoorthy N., Shyam Sunder A., Manisenthil Kumar K., Senthil Kumar M., Ganesh G., Chatterjee M. A review of metallothionein isoforms and their role in pathophysiology. World J. Surg. Oncol. 2011, 9:54. 10.1186/1477-7819-9-54.
41. Vasak M. Advances in metallothionein structure and functions. J. Trace Elem. Med. Biol. 2005, 19:13-17.
42. Waalkes M.P. Cadmium carcinogenesis. Mutat. Res. 2003, 10:107-120.
43. Waalkes M.P., Harvey M.J., Klaassen C.D. Relative in vitro affinity of hepatic metallothionein for metals. Toxicol. Lett. 1984, 20:33-39.
44. Yaman M. Comprehensive comparison of trace metal concentrations in cancerous and non-cancerous human tissues. Curr. Med. Chem. 2006, 13:2513-2525.
45. Yaman M., Atici D., Bakirdere S., Akdeniz I. Comparison of trace metal concentrations in malign and benign human prostate. J. Med. Chem. 2005, 48:630-634.
46. Yamasaki M., Nomura T., Sato F., Mimata H. Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells. Oncol. Rep. 2007, 18:1145-1153.
47. Zaichick S., Zaichick V. Trace elements of normal, benign hypertrophic and cancerous tissues of the human prostate gland investigated by neutron activation analysis. Appl. Radiat. Isot. 2012, 70:81-87.
48. Zuo P., Qu W., Cooper R.N., Goyer R.A., Diwan B.A., Waalkes M.P. Potential role of alpha-synuclein and metallothionein in lead-induced inclusion body formation. Toxicol. Sci. 2009, 111:100-108.